ARS Pharmaceutical’s CEO discusses how reformulating drugs and updating delivery design can improve the rate of patient adherence to medication.
Richard Lowenthal
Advertisement
Richard Lowenthal is CEO of ARS Pharmaceuticals.
Articles by Richard Lowenthal
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly Releases Updated Safety Data for Foundayo Following FDA’s Request
2
Johnson & Johnson’s Experience Navigating The Commissioner’s National Priority Voucher Program
3
How AI Is Transforming Drug Labeling
4
Pharmaceutical Executive Daily: Eli Lilly Releases Updated Safety Data for Foundayo
5